|
Synonyms: 2H7 | Ocrevus® | PRO70769 | RG1594
ocrelizumab is an approved drug (FDA (2017), EMA (2018))
Compound class:
Antibody
Comment: Ocrelizumab is a humanized IgG1 anti-CD20 monoclonal antibody, approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). This is the first therapeutic to gain approval for both of these forms of MS. Ocrelizumab is a modified version of rituximab, developed as a substitute in response to expiration of rituximab patent protection.
The submission documentation for the antibody's INN application contains the peptide sequences for the heavy and light chains of the antibody. BLAST searches of patented peptide sequences reveals identical matches with peptides claimed in patent WO2004056312, which resolve to clones 2H7.v16 and 2H7.v31 [1]. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Immunopharmacology Comments |
| Like rituximab, clinical efficacy of ocrelizumab in MS patients is believed to be achieved through depletion of populations of both CD20 positive B and T cells [2,6]. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Relapsing-remitting multiple sclerosis |
Disease Ontology:
DOID:2378 |
Ocrelizumab is approved to treat RRMS. | |
| Primary progressive multiple sclerosis |
Disease Ontology:
DOID:0050784 |
Ocrelizumab is approved to treat PPMS. | |
